Baird analyst Jack Allen lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $12 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its ALPHA3 Lymphodepletion decision and ALLO-329 data was pushed to 1H26.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength
- Allogene Therapeutics price target lowered to $7 from $9 at Piper Sandler
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
- Allogene downgraded to Market Perform from Outperform at Citizens JMP
- Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway